Metropolis Healthcare Limited
Metropolis Healthcare Limited operates in Healthcare Service Provider, part of the Healthcare sector. It booked ₹450 cr of revenue in its latest quarter (Q1 FY27) and kept 12.6% of sales as profit. It is the 3rd largest of 9 Healthcare Service Provider companies we track, by market value.
From the company's standalone segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
“the Group determines whether there exists clear the acquisition date that, if known, would have evidence of underlying reasons for classifying affected the amount recognised at that date.”
“To be a respected healthcare brand trusted by clinicians, patients and stakeholders.”
Healthier than 65% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 33–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 54
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
What if I invest in METROPOLIS?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 6%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹450 cr |
| Other Income | ₹5 cr |
| Total Income | ₹455 cr |
| Cost of Materials | ₹87 cr |
| Purchases of Stock-in-Trade | ₹0 cr |
| Employee Benefit Expense | ₹107 cr |
| Finance Costs | ₹6 cr |
| Depreciation & Amortisation | ₹32 cr |
| Other Expenses | ₹145 cr |
| Total Expenses | ₹378 cr |
| Profit before Tax | ₹78 cr |
| Tax Expense | ₹21 cr |
| Net Profit | ₹57 cr |
| Net margin on total income | 12.5% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 406 cr | 425 cr | 450 cr |
| Total income | 415 cr | 433 cr | 455 cr |
| Expenses | 349 cr | 363 cr | 378 cr |
| Profit before tax | 57 cr | 70 cr | 78 cr |
| Tax | 15 cr | 19 cr | 21 cr |
| Net profit (owners' share) | 41 cr | 51 cr | 57 cr |
| Net margin (owners' share, on revenue) | 10.2% | 12.0% | 12.6% |
| EPS (₹) | 7.99 | 2.46 | 2.73 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd. | ₹1,925 | ₹32,258 cr | 47.4 | 27.0% | 21.2% | — |
| Vijaya Diagnostic Centre Limited | ₹1,506 | ₹15,497 cr | 73.0 | 22.2% | 23.0% | — |
| Metropolis Healthcare Limitedthis company | ₹586 | ₹12,156 cr | 53.7 | 15.0% | 12.6% | — |
| Thyrocare Technologies Limited | ₹559 | ₹8,902 cr | 43.3 | 35.7% | 21.7% | — |
| Nephrocare Health Services Limited | ₹735 | ₹7,376 cr | 57.6 | 11.5% | 11.3% | — |
| Krsnaa Diagnostics Limited | ₹541 | ₹1,755 cr | 26.5 | 6.8% | 7.0% | — |
| Suraksha Diagnostic Limited | ₹329 | ₹1,713 cr | 32.9 | 21.3% | 14.8% | — |
| Health X Platform Limited | ₹300 | ₹954 cr | 93.8 | 1.6% | 0.6% | — |
| Gaudium IVF and Women Health Limited | ₹115 | ₹836 cr | 114.8 | 4.7% | 9.2% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹1 / share | 19 May 2026 |
| Bonus issue | 1:3 | 20 Mar 2026 |
| Dividend | ₹4 / share | 11 Nov 2025 |
| Dividend | ₹4 / share | 17 Nov 2023 |
| Dividend | ₹8 / share | 23 Feb 2023 |
| Dividend | ₹8 / share | 21 Feb 2022 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 6 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.